跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
查看斯高帕斯 (Scopus) 概要
胡 書維
助理教授
,
泌尿學科
主治醫師
,
衛生福利部雙和醫院
成員
,
臺北醫學大學泌尿腎臟研究中心
https://orcid.org/0000-0003-4382-5523
電子郵件
10352
s.tmu.edu
tw
h-index
124
引文
7
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2017
2026
每年研究成果
概覽
指紋
網路
研究成果
(22)
類似的個人檔案
(6)
指紋
查看啟用 Su-Wei Hu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Upregulation
100%
Percutaneous Nephrolithotomy
100%
Transitional Cell Carcinoma
100%
Carcinogenicity
100%
Stent Placement
100%
Extracorporeal Shockwave Therapy
100%
Randomized Clinical Trials
100%
Kidney Stone
69%
Urinary System
68%
Quality of Life
62%
Erectile Function
57%
Treatment Response
53%
Bladder Cancer
52%
Erectile Dysfunction
50%
Mediator Complex
50%
Dilation Procedure
50%
Systematic Review
50%
Neobladder
50%
Meta-Analysis
50%
Genitourinary System
50%
Extracorporeal Shock Wave Lithotripsy
50%
Hernioplasty
50%
Urethra Stenosis
50%
Urethrotomy
50%
Microhematuria
50%
Surgical Anastomosis
50%
Hemostat
50%
Extracorporeal
50%
Cystectomy
50%
Cell Damage
50%
Acute Kidney Injury
50%
Growth Differentiation Factor 15
50%
Diabetes
50%
Subgroup Analysis
50%
Oncology
50%
Chronic Pelvic Pain Syndrome
50%
Chronic Prostatitis
50%
Postoperative Pain
49%
Recurrent Disease
48%
Informed Consent
33%
Cancer Tissue
33%
Fluoroscopy
33%
International Index of Erectile Function
26%
Randomized Controlled Trial
25%
Prospective Study
25%
Seroma
25%
Surgical Infection
25%
Hematoma
25%
Retrospective Study
25%
Hyperlipidemia
21%
Biochemistry, Genetics and Molecular Biology
Transcriptome
65%
Cell Migration
61%
Carcinogenesis
59%
Promoter Region
58%
Survival Rate
58%
Upregulation
56%
Cell Motility
55%
Mediator Complex
50%
Genetics
50%
SRD5A1
50%
Interleukin 8
50%
Interleukin 6
50%
Growth Differentiation Factor
50%
Cell Damage
50%
E2F1
50%
TRAF2
50%
Binding Protein
50%
Protein-Protein Interaction
50%
Molecular Interaction
50%
Testosterone
50%
Acute Kidney Failure
50%
Genetic Model
30%
Overall Survival
22%
down Regulation
20%
Allele
20%
Inflammatory Cytokine
17%
Testosterone Metabolism
16%
Disease Free Survival
16%
Multi-Omics
15%
Small Hairpin RNA
12%
Small Interfering RNA
12%
Cancer Staging
12%
Transcription
11%
Drive
10%
Cell Proliferation
10%
Cochrane Library
10%
Embase
10%
Web of Science
10%
Medline
10%
Mediator
9%
Gene Expression Profiling
9%
Bioinformatics
9%
Progression Free Survival
8%
Transactivation
8%
E2F4
8%
Gleason Score
8%
Clinical Study
7%
Sample Size
7%
Androgen Receptor
7%
Arginine
7%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Bladder Cancer
69%
Diseases
60%
Recurrent Disease
60%
Carcinogenesis
60%
Carcinogenicity
50%
Transitional Cell Carcinoma
50%
Neoplasm
50%
Mouse Model
50%
Mediator Complex
50%
Focal Glomerulosclerosis
50%
Phosphodiesterase V Inhibitor
50%
Vardenafil
50%
Castration Resistant Prostate Cancer
50%
Hernia
50%
Interleukin 6
50%
Testosterone
50%
Disease Exacerbation
35%
Postoperative Pain
30%
Malignant Neoplasm
26%
Retrospective Study
20%
Prospective Study
20%
Surgical Infection
20%
Randomized Controlled Trial
20%
Hematoma
20%
Seroma
20%
Androgen
19%
Doxorubicin
18%
Tamsulosin
17%
Random Effects Model
15%
Short Hairpin RNA
14%
Therapy Resistance
14%
Biochemical Recurrence
12%
Therapeutic Effect
12%
Hemoperitoneum
10%
Femoral Hernia
10%
Recurrence Risk
10%
Inguinal Hernia
10%
Laceration
10%
Biological Marker
7%
Oncogenic activity
7%
Breast Cancer
7%
Antiandrogen
7%
Morbidity
7%
Abdominal Cancer
7%
Enzalutamide
7%
Abiraterone
7%
Overall Survival
6%
Multidrug Resistance Protein 1
6%
Docetaxel
6%
